UNIVERSE PHARMACEUTICALS INC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.51 USD | -2.71% |
|
+16.74% | +24.88% |
| 04-15 | Top Premarket Decliners | MT |
| 01-30 | Universe Pharmaceuticals INC Reports Earnings Results for the Full Year Ended September 30, 2023 | CI |
Valuation
| Fiscal Period: September | 2021 | 2022 | 2023 |
|---|---|---|---|
| Capitalization 1 | 53.72 | 12.29 | 3.464 |
| Enterprise Value (EV) 1 | 36.25 | -2.635 | -9.558 |
| P/E ratio | 4.14 x | -1.41 x | -0.56 x |
| Yield | - | - | - |
| Capitalization / Revenue | 1.12 x | 0.31 x | 0.11 x |
| EV / Revenue | 0.76 x | -0.07 x | -0.3 x |
| EV / EBITDA | 2.58 x | 0.38 x | 3.17 x |
| EV / FCF | -1,947,095 x | -661,467 x | -6,005,029 x |
| FCF Yield | -0% | -0% | -0% |
| Price to Book | 0.91 x | 0.26 x | 0.09 x |
| Nbr of stocks (in thousands) | 3,625 | 3,625 | 3,646 |
| Reference price 2 | 14.82 | 3.390 | 0.9500 |
| Announcement Date | 31/01/22 | 10/02/23 | 30/01/24 |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: September | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 28.51 | 33.23 | 30.7 | 47.98 | 40.14 | 32.31 |
| EBITDA 1 | 10.11 | 10.43 | 10.66 | 14.04 | -6.905 | -3.018 |
| EBIT 1 | 9.656 | 10.01 | 10.25 | 13.59 | -7.439 | -3.527 |
| Operating Margin | 33.87% | 30.14% | 33.39% | 28.32% | -18.53% | -10.92% |
| Earnings before Tax (EBT) 1 | 9.518 | 9.653 | 10.1 | 13.68 | -7.984 | -3.85 |
| Net income 1 | 7.603 | 7.551 | 7.558 | 11.32 | -8.737 | -6.163 |
| Net margin | 26.66% | 22.73% | 24.62% | 23.59% | -21.76% | -19.08% |
| EPS 2 | 2.851 | 2.832 | 2.834 | 3.578 | -2.410 | -1.700 |
| Free Cash Flow | - | 0.3751 | 4.922 | -18.62 | 3.984 | 1.592 |
| FCF margin | - | 1.13% | 16.03% | -38.8% | 9.92% | 4.93% |
| FCF Conversion (EBITDA) | - | 3.59% | 46.17% | - | - | - |
| FCF Conversion (Net income) | - | 4.97% | 65.12% | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 17/08/20 | 17/08/20 | 24/02/21 | 31/01/22 | 10/02/23 | 30/01/24 |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: September | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | 3.57 | 0.66 | 7.41 | 17.5 | 14.9 | 13 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow | - | 0.38 | 4.92 | -18.6 | 3.98 | 1.59 |
| ROE (net income / shareholders' equity) | - | 68.4% | 45.5% | 28.4% | -16.6% | -14.3% |
| ROA (Net income/ Total Assets) | - | 27.3% | 27.5% | 17.2% | -7.17% | -3.91% |
| Assets 1 | - | 27.7 | 27.51 | 65.94 | 121.8 | 157.7 |
| Book Value Per Share 2 | 3.630 | 4.640 | 7.800 | 16.30 | 12.80 | 10.90 |
| Cash Flow per Share 2 | 2.320 | 1.190 | 3.770 | 2.230 | 1.580 | 1.460 |
| Capex 1 | 0.15 | 0.09 | 0.05 | 13.5 | 0.09 | 0.04 |
| Capex / Sales | 0.51% | 0.26% | 0.17% | 28.2% | 0.23% | 0.14% |
| Announcement Date | 17/08/20 | 17/08/20 | 24/02/21 | 31/01/22 | 10/02/23 | 30/01/24 |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| +24.88% | 9.1M | |
| +42.64% | 6.28B | |
| -15.52% | 4.51B | |
| +8.35% | 3.35B | |
| -11.10% | 3.13B | |
| -4.12% | 2.47B | |
| +46.46% | 1.96B | |
| -7.97% | 1.68B | |
| -1.07% | 1.63B | |
| -11.56% | 1.56B |
- Stock Market
- Equities
- UPC Stock
- Financials Universe Pharmaceuticals INC
